Clinical trial · Observational
An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer
A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer
NCT01661153CI-TRIAL-00029269completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective observational study will evaluate the use in clinical practice, efficacy and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients with HER2-negative metastatic breast cancer. Data will be collected from eligible patients for up to 2.5 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- approximately 2.5 years
Secondary outcomes (2)
- measure
- Dosage/schedule/number of cycles of Avastin treatment in clinical practice
- timeFrame
- approximately 2.5 years
- measure
- Safety: Incidence of adverse events
- timeFrame
- approximately 2.5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Locally recurrent or metastatic breast cancer * No prior treatment for metastatic or locally recurrent disease * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Exclusion Criteria: * History or clinical evidence of brain metastases * Pregnancy * Uncontrolled hypertension ( systolic \> 150 mmHg and/or diastolic \> 100 mmHg) or clinically significant (i.e. active) cardiovascular disease * Major surgical procedure or significant traumatic injury within 28 days prior to enrolment
References
Publications (0)
Data not yet available
No reference posted for this study.